好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A new definition of seizure clusters based on temporal clustering patterns in seizure diaries
Epilepsy/Clinical Neurophysiology (EEG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
6-028

To propose a new data-driven approach to defining seizure clusters, and to compare the performance of current seizure cluster definitions.

 

Seizure clusters are often encountered in people with severe or poorly controlled epilepsy. There is no uniform consensus on how a seizure cluster should be defined. This study proposes a new data-driven approach to defining seizure clusters and evaluates current definitions for accuracy in identifying seizure clusters.

 

Clinical and electrographic seizure diary data collected by SeizureTracker.com and the Responsive Neurostimulation (RNS) system were analyzed. Hurst statistics were used to quantitate seizure clustering in clinical seizures. Conventional definitions were evaluated for sensitivity and specificity for identifying seizures exhibiting statistical evidence of clustering. The association between time since the last seizure cluster and the number of subsequent clustered seizures was evaluated for clinical and electrographic seizures.

 

A total of 564,510 clinical seizures from 1,826 people with self-reported epilepsy in SeizureTracker.com and 360,120 electrographic seizures from 14 people with epilepsy implanted with the RNS system were analyzed. Empirical seizure cluster percentiles based on the Hurst exponent are provided and proposed as a standardized measure of seizure cluster tendency. Conventional definitions varied widely in ability to identify clusters, with significant variability in the ISI threshold needed to identify statistical clusters. The number of seizures in a given cluster followed a power law in relation to time since the last seizure cluster for clinical and electrographic seizures.

 

We propose a data-driven approach to identifying seizure clusters which accounts for individual variability in baseline seizure frequency and avoids prechosen thresholds. These results provide unique insight into the prognostic significance of current seizure cluster definitions and proposes a new individualized approach to defining seizure clusters.

 

Authors/Disclosures
Sharon Chiang, MD, PhD (UCSF)
PRESENTER
Dr. Chiang has stock in EpilepsyAI. Dr. Chiang has received research support from UCSF Clinical and Translational Science Institute UL1 TR001872. The institution of Dr. Chiang has received research support from NIH R25 NS070680 .
Sheryl R. Haut, MD (Albert Einstein College of Medicine) Dr. Haut has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ventus. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVe. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Iqvia.
Victor Ferastraoaru, MD (Montefiore Medical Ctr-Neurology Dept) Dr. Ferastraoaru has nothing to disclose.
Vikram Rao, MD (UC San Francisco) Dr. Rao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precisis GmbH. Dr. Rao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for iVEAcare. Dr. Rao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace, Inc.. Dr. Rao has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rao has stock in Novela Neurotechnologies. Dr. Rao has stock in EnlitenAI. Dr. Rao has stock in Doximity, Inc. Dr. Rao has stock in Theta Neurotech. Dr. Rao has stock in Encephalogix.
Maxime Baud, MD, PhD (University of California, SF (UCSF)) No disclosure on file
William H. Theodore, MD, FAAN Dr. Theodore has a non-compensated relationship as a Treasurer and vice president with American Epilepsy Society that is relevant to AAN interests or activities.
No disclosure on file
Daniel Goldenholz, MD, PhD (Beth Israel Deaconess Medical Center) Dr. Goldenholz has received personal compensation in the range of $0-$499 for serving as a Consultant for Neuro Event Labs. Dr. Goldenholz has received personal compensation in the range of $0-$499 for serving as a Consultant for IDR. Dr. Goldenholz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Livanova . Dr. Goldenholz has received personal compensation in the range of $0-$499 for serving as a Consultant for Health Advances . Dr. Goldenholz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AAN. Dr. Goldenholz has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ACNS. Dr. Goldenholz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AES. Dr. Goldenholz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Nebraska Neurological Society . The institution of Dr. Goldenholz has received research support from NIH. The institution of Dr. Goldenholz has received research support from BIDMC. Dr. Goldenholz has a non-compensated relationship as a advisor with Eysz that is relevant to AAN interests or activities. Dr. Goldenholz has a non-compensated relationship as a advisor with Epilepsy AI that is relevant to AAN interests or activities.